Bone sialoprotein, matrix metalloproteinase 2, and α vβ3 integrin in osteotropic cancer cell invasion

Journal of the National Cancer Institute

Volumn 96, Issue 12, 2004, Pages 956-965

  Karadag, Abdullah ^a   Ogbureke, Kalu U E ^a   Fedarko, Neal S ^a,b   Fisher, Larry W ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA5 INTEGRIN; ARGINYLGLYCYLASPARTYLSERINE; BETA3 INTEGRIN; ENZYME ANTIBODY; ENZYME INHIBITOR; GELATINASE A; MATRIGEL; MATRIX METALLOPROTEINASE; MATRIX PROTEIN; OSTEOPONTIN; PROTEIN ANTIBODY; SIALOPROTEIN; BONE SIALOPROTEIN; SIALOGLYCOPROTEIN; VITRONECTIN RECEPTOR;

ANTIBODY SPECIFICITY; ARTICLE; BONE CELL; BREAST TUMOR; CANCER INVASION; CARCINOMA CELL; CELL ASSAY; CELL INVASION; CELL SURFACE; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE INACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN SITU HYBRIDIZATION; IN VITRO STUDY; LUNG TUMOR; PAPILLOMA; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; THYROID TUMOR; TUMOR CELL LINE; BONE TUMOR; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; MALE; METABOLISM; METASTASIS; NEOPLASM; OSTEOSARCOMA; POLYACRYLAMIDE GEL ELECTROPHORESIS; SERODIAGNOSIS;

BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IN SITU HYBRIDIZATION; INTEGRIN ALPHAVBETA3; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; NEOPLASM INVASIVENESS; NEOPLASMS; OSTEOSARCOMA; PRECIPITIN TESTS; PROSTATIC NEOPLASMS; SIALOGLYCOPROTEINS; THYROID NEOPLASMS;

EID: 2942679170     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh169     Document Type: Article

References (54)

1. Fisher LW, Torchia DA, Fohr B, Young MF, Fedarko NS. Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem Biophys Res Commun 2001;280:460-5.
2. Fisher LW, Fedarko NS. Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins: special issue: 7th International Conference on the Chemistry and Biology of Mineralized Tissues. Connect Tissue Res 2003;44 Suppl 1:33-40.
3. Bianco P, Fisher LW, Young MF, Termine JD, Robey PG. Expression of bone sialoprotein (BSP) in developing human tissues. Calcif Tissue Int 1991;49:421-6.
4. MacDougall M. Refined mapping of the human dentin sialophosphoprotein (DSPP) gene within the critical dentinogenesis imperfecta. type II and dentin dysplasia type II loci. Eur J Oral Sci 1998;106 Suppl 1:227-33.
5. Omigbodun A, Daiter E, Walinsky D, Fisher L, Young M, Hoyer J, et al. Regulated expression of osteopontin in human trophoblasts. Ann N Y Acad Sci 1995;760:346-9.
6. Hampel DJ, Sansome C, Romanov VI, Kowalski AJ, Denhardt DT, Goligorsky MS. Osteopontin traffic in hypoxic renal epithelial cells. Nephron Exp Nephrol 2003;94:e66-76.
7. Dhanireddy R, Senger D, Mukherjee BB, Mukherjee AB. Osteopontin in human milk from mothers of premature infants. Acta Paediatr 1993;82: 821-2.
8. Gravallese EM. Osteopontin: a bridge between bone and the immune system. J Clin Invest 2003;112:147-9.
9. Fedarko NS, Fohr B, Robey PG, Young MF, Fisher LW. Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack. J Biol Chem 2000;275:16666-72.
10. Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996;271:509-12.
11. Jain A, Karadag A, Fohr B, Fisher LW, Fedarko NS. Three SIBLINGs (small integrin-binding ligand, N-linked glycoproteins) enhance factor H's cofactor activity enabling MCP-like cellular evasion of complement-mediated attack. J Biol Chem 2002;277:13700-8.
12. Ue T, Yokozaki H, Kitadai Y, Yamamoto S, Yasui W, Ishikawa T, et al. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 1998;79:127-32.
13. Zohar R, Suzuki N, Suzuki K, Arora P, Glogauer M, McCulloch CA, et al. Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration. J Cell Physiol 2000;184:118-30.
14. Bellahcene A, Merville MP, Castronovo V. Expression of bone sialoprotein, a bone matrix protein, in human breast cancer. Cancer Res 1994;54: 2823-6.
15. Waltregny D, Bellahcene A, Van Riet I, Fisher LW, Young M, Fernandez P, et al. Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. J Natl Cancer Inst 1998;90: 1000-8.
16. Bellahcene A, Maloujahmoum N, Fisher LW, Pastorino H, Tagliabue E, Menard S, et al. Expression of bone sialoprotein in human lung cancer. Calcif Tissue Int 1997;61:183-8.
17. Bellahcene A, Albert V, Pollina L, Basolo F, Fisher LW, Castronovo V. Ectopic expression of bone sialoprotein in human thyroid cancer. Thyroid 1998;8:637-41.
18. Riminucci M, Corsi A, Peris K, Fisher LW, Chimenti S, Bianco P. Coexpression of bone sialoprotein (BSP) and the pivotal transcriptional regulator of osteogenesis, Cbfa1/Runx2, in malignant melanoma. Calcif Tissue Int 2003.
19. Bellahcene A, Menard S, Bufalino R, Moreau L, Castronovo V. Expression of bone sialoprotein in primary human breast cancer is associated with poor survival. Int J Cancer 1996;69:350-3.
20. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001;7:4060-6.
21. Matrisian LM. Cancer biology: extracellular proteinases in malignancy. Curr Biol 1999;9:R776-8.
22. Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999;43 Suppl:S42-51.
23. Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 1996;85:683-93.
24. Yu Q, Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 1999;13:35-48.
25. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11-25.
26. Aplin AE, Howe AK, Juliano RL. Cell adhesion molecules, signal transduction and cell growth. Curr Opin Cell Biol 1999;11:737-44.
27. Hood JD, Cheresh DA. Role of integrins in cell migration and invasion. Nature Rev Cancer 2002;2:91-100.
28. Gasparini G, Brooks PC, Biganzoli E, Vermeulen PB, Bonoldi E, Dirix LY, et al. Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer. Clin Cancer Res 1998;4:2625-34.
29. Fedarko NS, Jain A, Karadag A, Fisher LW. Three small integrin binding ligand N-linked glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinases. FASEB J 2004;18:734-6.
30. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987;47:3239-45.
31. Fisher LW, McBride OW, Termine JD, Young MF. Human bone sialoprotein. Deduced protein sequence and chromosomal localization. J Biol Chem 1990;265:2347-51.
32. Kiefer MC, Bauer DM, Barr PJ. The cDNA and derived amino acid sequence for human osteopontin. Nucleic Acids Res 1989;17:3306.
33. Hirst KL, Ibaraki-O'Connor K, Young MF, Dixon MJ. Cloning and expression analysis of the bovine dentin matrix acidic phosphoprotein gene. J Dent Res 1997;76:754-60.
34. Becker TC, Noel RJ, Coats WS, Gomez-Foix AM, Alam T, Gerard RD, et al. Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol 1994;43:161-89.
35. Fitzgerald LA, Poncz M, Steiner B, Rall SC Jr, Bennett JS, Phillips DR. Comparison of cDNA-derived protein sequences of the human fibronectin and vitronectin receptor alpha-subunits and platelet glycoprotein IIb. Biochemistry 1987;26:8158-65.
36. Fitzgerald LA, Steiner B, Rall SC Jr, Lo SS, Phillips DR. Protein sequence of endothelial glycoprotein IIIa derived from a cDNA clone. Identity with platelet glycoprotein IIIa and similarity to "integrin". J Biol Chem 1987; 262:3936-9.
37. Oldberg A, Franzen A, Heinegard D, Pierschbacher M, Ruoslahti E. Identification of a bone sialoprotein receptor in osteosarcoma cells. J Biol Chem 1988;263:19433-6.
38. Collier IE, Wilhelm SM, Eisen AZ, Marmer BL, Grant GA, Seltzer JL, et al. H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J Biol Chem 1988;263:6579-87.
39. Pyke C, Ralfkiaer E, Huhtala P, Hurskainen T, Dano K, Tryggvason K. Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization. Cancer Res 1992; 52:1336-41.
40. Monteagudo C, Merino MJ, San-Juan J, Liotta LA, Stetler-Stevenson WG. Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue. Am J Pathol 1990;136:585-92.
41. Lochter A, Galosy S, Muschler J, Freedman N, Werb Z, Bissell MJ. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol 1997;139:1861-72.
42. Belien AT, Paganetti PA, Schwab ME. Membrane-type 1 matrix metalloprotease (MT1-MMP) enables invasive migration of glioma cells in central nervous system white matter. J Cell Biol 1999;144:373-84.
43. Ala-Aho R, Johansson N, Baker AH, Kahari VM. Expression of collagenase-3 (MMP-13) enhances invasion of human fibrosarcoma HT-1080 cells. Int J Cancer 2002;97:283-9.
44. Hotary K, Allen E, Punturieri A, Yana I, Weiss SJ. Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3. J Cell Biol 2000;149:1309-23.
45. Klein CE, Steinmayer T, Kaufmann D, Weber L, Brocker EB. Identification of a melanoma progression antigen as integrin VLA-2. J Invest Dermatol 1991;96:281-4.
46. Deryugina EI, Bourdon MA, Luo GX, Reisfeld RA, Strongin A. Matrix metalloproteinase-2 activation modulates glioma cell migration. J Cell Sci 1997;110:2473-82.
47. Deryugina EI, Bourdon MA, Jungwirth K, Smith JW, Strongin AY. Functional activation of integrin alpha V beta 3 in tumor cells expressing membrane-type 1 matrix metalloproteinase. Int J Cancer 2000;86:15-23.
48. Sung V, Stubbs JT 3rd, Fisher L, Aaron AD, Thompson EW. Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the alpha(v)beta3 and alpha(v)beta5 integrins. J Cell Physiol 1998;176:482-94.
49. Byzova TV, Kim W, Midura RJ, Plow EF. Activation of integrin alpha (V)beta(3) regulates cell adhesion and migration to bone sialoprotein. Exp Cell Res 2000;254:299-308.
50. Xuan JW, Hota C, Shigeyama Y, D'Errico JA, Somerman MJ, Chambers AF. Site-directed mutagenesis of the arginine-glycine-aspartic acid sequence in osteopontin destroys cell adhesion and migration functions. J Cell Biochem 1995;57:680-90.
51. Chambers AF, Wilson SM, Kerkvliet N, O'Malley FP, Harris JF, Casson AG. Osteopontin expression in lung cancer. Lung Cancer 1996; 15:311-23.
52. Tuck AB, O'Malley FP, Singhal H, Harris JF, Tonkin KS, Kerkvliet N, et al. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 1998;79:502-8.
53. Chaplet M, De Leval L, Waltregny D, Detry C, Fornaciari G, Bevilacqua G, et al. Dentin matrix protein 1 is expressed in human lung cancer. J Bone Miner Res 2003;18:1506-12.
54. Albini A. Tumor and endothelial cell invasion of basement membranes. The matrigel chemoinvasion assay as a tool for dissecting molecular mechanisms. Pathol Oncol Res 1998;4:230-41.